Growth of new blood vessels (angiogenesis), required for all tumor growth, is stimulated by the expression of vascular endothelial growth factor (VEGF). VEGF is up-regulated in all known solid tumors but also in atherosclerosis, diabetic retinopathy, arthritis, and many other conditions. Conventional VEGF isoforms have been universally described as proangiogenic cytokines. Here, we show that an endogenous splice variant, VEGF 165 b, is expressed as protein in normal cells and tissues and is circulating in human plasma. We also present evidence for a sister family of presumably inhibitory splice variants. Moreover, these isoforms are down-regulated in prostate cancer. We also show that VEGF 165 b binds VEGF receptor 2 with the same affinity as VEGF 165 
INTRODUCTION
Growth of new blood vessels (angiogenesis) is required for all tumor growth, as well as in nonneoplastic pathologies such as neointimal hyperplasia, arthritis, atherosclerosis, and diabetes (1) . Angiogenesis is stimulated by the expression of vascular growth factors, the most commonly expressed of which is vascular endothelial growth factor (VEGF). VEGF mRNA and protein are up-regulated in all known solid tumors as in nearly all other known instances of angiogenesis (2, 3) . Multiple isoforms of VEGF are generated by alternative splicing (ref. 4 ; Fig. 1 ). The multiple isoforms of conventional vascular endothelial growth factor-A result from differential splicing of pre-mRNA from eight exons resulting in at least six mRNA and (presumed) peptide species identified by the exon composition and amino acid length of the final proteins (ref. 5 ; Fig. 1 ). All conventional splice variants studied, including the most common isoform, VEGF 165 , have been shown to be proangiogenic, and they exert this effect by stimulating endothelial cell migration, proliferation, and lumen formation and are potent proangiogenic vasodilators and mediators of increased microvascular permeability (6, 7) . These effects are mediated principally by activation of VEGF receptor 2 (VEGFR-2)(KDR/flk1; refs. 3, 8) . Endothelial cells also express VEGFR-1; however, the specific role of this receptor in endothelial physiology is less well defined (3, 8) .
Of all of the growth factors involved in angiogenesis, VEGF appears to play an irreplaceable role. Transgenic knockout models of only a single gene copy are commensurate with embryonic lethality (9, 10) . VEGF-A is highly up-regulated in all cases of pathological angiogenesis yet described (11) , and these include the major killersnot only cancer but also cardiovascular disease and diabetes-in the developed world (e.g., refs. 12, 13). It is also required for physiological angiogenesis, for example, in embryonic and placental development. VEGF 189 , VEGF 165 , and VEGF 121 are commonly overexpressed, but VEGF 165 appears to predominate quantitatively and functionally in most angiogenic states.
VEGF was originally described as a growth and survival factor for endothelial cells. It is, however, becoming increasingly apparent that VEGF is also an important factor in the function, physiology, and pathology of cancer cells themselves, as well as a wide variety of nonneoplastic cell types, including the migration and growth of neurones (14, 15) and migration of monocytes (16) . For instance, it has been shown to act as an autocrine survival factor for breast and prostate cancer cells (17, 18) but also for hematopoietic stem cells (19) and podocytes (20) .
Considerable interest therefore results from the realization that VEGF expression is highly regulated at both mRNA and protein levels in tissues that are not normally angiogenic, e.g., cerebellum (21) , prostate (22) , pancreatic islets (23) , and glomeruli (24) . While investigating this paradox, we recently discovered mRNA encoding a novel isoform, VEGF 165 b, which did not appear to stimulate endothelial cell proliferation or migration and was down-regulated in renal cell carcinoma (25) . This isoform, formed by distal splice site selection in the terminal exon of VEGF, predicts an open reading frame encoding an alternate COOH-terminal sequence but the same number of amino acids in the mature protein (Fig. 1B) . This predicted the translation of a protein of the same length as VEGF 165 , but with a different sequence and hence possibly a different mechanism of action. VEGF 165 b was so named because it also contains 165 amino acids. However, the COOH-terminal six amino acids usually coded for by exon 8 (CDKPRR) would be replaced by six different amino acids (SLTRKD) coded for by 18 bases of mRNA spliced 66 bases downstream of the usual acceptor splice site for exon 8, if this isoform was translated. We initially termed this new open reading frame exon 9, although there is no true intron between the two reading frames, and the alternative splicing should perhaps more correctly be referred to as exon 8 proximal and distal splicing sites. This isoform was identified serendipitously, and the high degree of homology between VEGF 165 b and VEGF 165 (96%) perhaps explains the elusiveness of this isoform until now. VEGF 165 b and VEGF 165 would not be distinguished in most nucleic acid and protein assays but would be assumed to be the same product.
It has been previously shown that the COOH terminus of VEGF is necessary for determining mitogenic potency (26) . We therefore speculated that the novel COOH terminus would influence function and subsequently showed that conditioned media from cells expressing synthetic, recombinant VEGF 165 b inhibited VEGF 165 -mediated endothelial cell proliferation and migration in vitro and vasodilatation ex vivo (25) . The mechanisms by which this occurred, however, and whether VEGF 165 b was a true endogenous inhibitor (i.e., it was produced as an endogenous protein and could block angiogenesis in vivo) were not shown. Moreover, the discovery of the exon 8 distal splicing site predicted but did not demonstrate the existence of an entire family of sister isoforms (VEGF xxx b), all with inhibitory potential. We have therefore carried out experiments to determine (a) whether VEGF 165 
MATERIALS AND METHODS
Recombinant Human VEGF 165 b was obtained from R&D Systems (Abingdon, United Kingdom). This was produced in the same manner as commercially available recombinant human VEGF 165 .
Receptor Binding Assays
Immulon II HB Flat well 96-well plates were incubated with 100 L of 1 g⅐mL -1 VEGFR-2-Fc Chimera (R&D Systems) overnight, and washed three times with 1ϫ PBS (pH 7.4), supplemented with 0.05% Tween 20 (PBS-T; Sigma-Aldrich, Poole, Dorset, United Kingdom). For cell assays human umbilical vascular endothelial cells were grown to confluency in 96-well plates. The plate was blocked with 800 L of 3% BSA for 2 hours and again washed twice with PBS-T. A total of 10 ng⅐mL -1 125 I-VEGF 165 and 100 Ci⅐mL -1 was mixed with increasing concentrations of VEGF 165 b or VEGF 165 , and 100 L added to the ELISA plate. This was incubated for 4 h at room temperature, then gently washed with PBS three times. 10% SDS was then added, and the solution transferred to a gamma counter for assays. Counts were expressed as the percent of the counts of wells incubated with 125 I-VEGF 165 alone.
Cell Culture
Terminally differentiated conditionally immortalized glomerular visceral epithelial cells (podocytes, a kind gift of Moin A. Saleem, Children's Academic Renal Unit, Southmead Hospital, University of Bristol, Bristol, United Kingdom) were cultured as described previously (27) . Cells were washed and collected with PBS followed by centrifugation at 3000 rpm for 5 minutes and protein extracted as described below.
Tissue and Blood Samples
Blood was collected from normal healthy volunteers ages 21 to 40. Blood was taken into EDTA vacutainers and centrifuged at 4000 ϫ g for 10 minutes. Plasma was removed from the erythrocytes and stored at Ϫ80°C until defrosted and used for ELISA. Prostate chips were obtained from patients undergoing transurethral resection of the prostate for lower urinary tract symptoms. Samples were frozen at Ϫ80°C immediately until processed. Patients with benign prostatic hyperplasia and advanced prostate cancer (stage T 3 N x M 0 -1 ; UICC2002) were included. Chips were defrosted on ice and manually sliced with a sterile blade. The mass of each tissue was recorded, and samples were homogenized on ice for 10 minutes and protein extracted as described below. Rat lungs were removed from animals that were humanely killed by cervical dislocation. An equivalent volume of PBS containing either saline, 1 nmol/L VEGF 165 , 1 nmol/L VEGF 165 b, or 1 nmol/L VEGF 165 and 1 nmol/L VEGF 165 b was added to each sample. The samples were chopped up crudely on ice with a sterile scalpel blade and then incubated for 20 minutes at 37°C in a shaking incubator. After this they were snap-frozen in liquid nitrogen.
Protein Extraction
Lysis buffer (1 L/mg tissue; 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L Va 3 N0 4 , 1.0 g/mL leupeptin, 1 g/mL aprotonin, and 1 g/mL pepstatin, in radioimmunoprecipitation assay buffer) was added to cells and prostate tissue and homogenized on ice for 10 minutes, placed at 4°C on an agitating rocker plate for 20 minutes, removed and placed in ice for an additional 60 minutes, and agitated every 10 to 15 minutes.
Samples were centrifuged at 4°C for 15 minutes at 13,000 rpm, and the supernatant collected and stored at Ϫ20°C. Protein concentrations were determined by photospectrometry. For rat lung tissue, after thawing, the samples were mixed gently, excess liquid was removed, and protein extracted by adding an equal volume of lysis buffer (140 mmol/L NaCl, 3 mmol/L KCl, 10 mmol/L Na 2 HPO 4 , 2.7 mmol/L KH 2 PO 4 , 1% NP40/IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L sodium orthovanadate, 20 g⅐mL -1 aprotinin, 10 g⅐mL -1 leupeptin, and 10 g⅐mL -1 pepstatin) and homogenizing on ice for 10 minutes. Homogenates were left at 4°C on a rocker for 1 hour and then spun down in a benchtop centrifuge for 15 minutes at 13,000 rpm at 4°C to separate the protein from cell debris.
Production of Monoclonal Antibody to VEGF 165 b
Peptide Fragments and Immunization. Synthetic peptide fragments of the nine amino acid COOH-terminal sequence of VEGF 165 b were coupled to keyhole limpet hemocyanin (Department of Biochemistry, University of Bristol) serving as carrier molecules and were then used to immunize 6 to 8-week-old female BALB/c mice. The animals received s.c. injections of 100 g of peptide-keyhole limpet hemocyanin conjugates in Freund's Complete Adjuvant on days 1, 21, and 42 and boosted by i.p injections at 63, 64, and 65 days. Mice were killed humanely the next day and spleens collected. Splenocytes were fused to the NS0 mouse myeloma cell line with polyethylene glycol. Fused cells were cultured in 96-well plates for 2 weeks. Cells from positive wells determined by ELISA screening were serially diluted in 96-well plates and cultured in 10% DMEM and hybridomacloning enhancing factor. The same procedure was repeated until 100% positivity from each plate was achieved three consecutive times. Screening was done in Immulon II HB Flat well 96-well plates (Thermo Life Sciences Ltd.), coated with goat antihuman VEGF antibody (0.8 g/mL in PBS; R&D Systems). After washing with PBS-T, 100 L of 2 ng/mL VEGF 165 b (from the conditioned medium of transfected cells) or recombinant VEGF 165 (R&D systems) were added to the wells and incubated for 15 minutes at 37°C with shaking. After washing, 100 L of conditioned medium from hybridoma cells were added and incubated for 15 minutes at 37°C with shaking. After washing, 100 L of horseradish peroxidase (HRP)-conjugated goat antimouse immunoglobulins (1:1000 in 1% BSA/PBS; DAKO, Carpinteria, CA) were added and incubated for 15 minutes at 37°C with shaking. After final washing, O-phenylenediamine dihydrochloride substrate (Sigma Chemical Co., St. Louis, MO) was added, and the absorbance at 492 nm was measured using a plate reader. To purify and concentrate the monoclonal antibodies, the selected clones of hybridoma cells were cultured in DMEM (Sigma Chemical Co.) containing 10% bovine IgG-depleted FCS (Hyclone, Logan, UT) with 100 units of penicillin, 100 g of streptomycin, and 2 mmol/L L-glutamine. Monoclonal antibodies were purified on protein-G Sepharose 4 Fast Flow columns (Amersham Biosciences). The antibodies were concentrated with vivaspin 20 (Vivascience AG, Hannover, Germany) and finally dissolved in PBS.
SDS-PAGE
All protein samples were resuspended in SDS sample buffer, heated at 100°C for 5 minutes, and subsequently resolved by SDS-PAGE and transferred to polyvinylidene difluoride membrane. The membranes were blocked with PBS, 10% Marvel, and 0.05% Tween 20 for 1 hour at room temperature, followed by overnight incubation at 4°C with the primary antibody (see below). Mitogen-activated Protein Kinase and AKT Phosphorylation. Membranes containing protein extracted from CHO cells transfected with VEGFR-2 (Flk) were probed with mouse anti-phospho-p44/42 (Cell Signaling; 1:500) or rabbit anti-phospho-AKT (1:200 and 1:500; BD Bioscience, PharMingen, San Diego, CA) by overnight incubation at 4°C. After washing in PBS-T, the blots were then incubated for 1 hour with HRP-conjugated goat antimouse or goat antirabbit (1:2000; Pierce) antibody, and visualized as above. Subsequently, membranes were stripped with enhanced chemiluminescence stripping buffer at 50°C for 30 minutes with agitation followed by a visualization step to ensure that all of the immunoreactive bands had been removed. The blots were blocked with 10% Marvel-PBS-T for 1 hour at room temperature on a roller followed by overnight incubation at 4°C on a rocker with mouse anti-p44/42 (1:500; Cell Signaling) or mouse anti-protein kinase B␣/AKT1 (PkB-175, 1:400; Sigma) washed and incubated for 1 hour with HRP-conjugated goat antimouse antibody, as above.
Western Blot and Immunodetection
Immunoreactive bands were visualized by chemiluminescence with a compact X4 developer from X-ograph imaging systems. Densitometry, measured using the NIH image software, was used to determine the mean intensity of the immunoreactive bands.
Immunohistochemistry
Immunohistochemistry was done on formalin-fixed, paraffin-embedded tissue derived from the normal pole of nephrectomy specimens. Five-micrometer thick sections were cut and mounted onto poly-L-lysine-coated glass slides. Sections were dewaxed, rehydrated, washed in distilled water, and then rinsed in 0.01 mol/L Tris-buffered saline (PBS, pH 7.2). Sections were microwave heated in 0.1 mmol/L Tris-HCl/2 mmol/L EDTA pH buffer (pH 9.0) at 650 watts for two cycles of 8 minutes, washed twice with distilled water for 5 minutes, then treated with 0.015% trypsin (Invitrogen Corp.) diluted in PBS for 15 minutes at 37°C. Sections were washed twice, incubated with 3% hydrogen peroxide solution, washed twice with PBS, blocked with 3% BSA (A4378; Sigma) in PBS and then with 1.5% normal horse serum (S-2000; Vector Lab, Peterborough, United Kingdom) in PBS. Sections were then incubated with 2 g/mL mouse monoclonal anti-VEGF 165 b IgG or a normal mouse IgG (I8765; Sigma) as a negative control diluted in 1.5% normal horse serum in PBS overnight at ϩ4°C in a humid chamber. Sections were washed twice in 0.05% Tween Tris-buffered saline [PBS/Tween (pH7.2)] for 5 minutes and were treated with both the nonspecific blocking solution, as above, then incubated with biotinylated antimouse-IgG (BA2000; Vector Lab) at a 1:750 dilution in 1.5% normal horse serum in PBS at room temperature for 30 minutes in a humid chamber. Sections were washed twice in PBS/Tween, 5 minutes per wash, and then incubated with Vectastain ABC solution (PK4000; Vector Lab) for 30 minutes at room temperature followed by two additional washes in PBS/Tween. Sections were treated with 3,3Ј-diaminobenzidine peroxidase substrate solution (SK4100; Vector Lab) until color was visualized. Rinsing in distilled water stopped the reaction. Sections were washed twice in distilled water for 5 minutes, then counterstained in hematoxylin for 5 minutes, washed, dehydrated, cleared in xylene, mounted with DPX, and glass coverslipped. Sections were examined under oil immersion with a ϫ100 objective on a Nikon Eclipse E-400 microscope, and images were captured using a Coolpix 995 digital camera and a DN-100 digital imaging system (Nikon Instruments, Surrey, United Kingdom).
mRNA Extraction and Reverse Transcription-PCR
Fifty to 100 mg of transurethral resection of the prostate tissue collected as above was homogenized in Trizol reagent (Life Technologies, Inc., Rockville, MD) and mRNA extracted by using the method of Chomczyinski and Sacchi (28) . Eight microliters of RNA were treated with RNase free DNase (Promega) according to the manufacturer's guidelines to prevent genomic DNA contamination. mRNA was reverse transcribed using Moloney murine leukemia virus reverse transcriptase and poly-d(T). cDNA was then amplified using intronspanning primers that detect VEGF 165 b only, even in the presence of 1000ϫ greater concentration of VEGF 165 mRNA (25) . One mol/L of a primer complementary to exon 4 (5Ј-GAGATGAGCTTCCTACAGCAC-3Ј) and to exon 9 and the terminal 5 nucleotides of exon 7, incorporating a HindIII restriction site at the 5Ј-end (exon9/7, 5Ј-TTAAGCTTTCAGTCTTTCCTG-GTGAGAGATCTGCA-3Ј), together with 1.2 mmol/L MgCl 2 , 200 mol/L deoxynucleoside triphosphates, and 1 unit of TaqDNA polymerase (Abgene) were used in reactions which were cycled 35 times, denaturing at 94°C for 30 seconds, annealing at 63°C for 30 seconds, and extending at 72°C for 60 seconds. PCR products were run on 3% agarose gels containing 0.5 g/mL ethidium bromide and visualized under a UV transilluminator. This reaction consistently resulted in one amplicon at ϳ220 bp (consistent with VEGF 165 b). A reverse primer complementary to exon 8 (5Ј-TCACCGCCTCGGCTTGT-CACAT-3Ј) was also used that detects VEGF 165 but not VEGF 165 b. Finally, cDNA was also amplified with primers designed to pick up all of the VEGF isoforms. One mol/L of primers complementary to exon 2 (5Ј-GGAGGGCA-GAATCATCACGAAG-3Ј) and exon 3 (5Ј-CACACAGGATGGCTTGAA-GATG-3Ј) were used. PCR conditions were as above but annealing at 55°C.
ELISA
A total of 0.8 g/mL pan-VEGF capture antibody (Duoset VEGF ELISA DY-293; R&D Systems) diluted in 1ϫ PBS (pH 7.4) was adsorbed onto 96-well sterile plates (655161; Greiner Bio-one Ltd., Gloucester, United Kingdom) overnight at room temperature (100 L/well). The plates were washed three times with 1ϫ PBS-T before and after blocking with 300 L/well 1% BSA in PBS for 2 hours at 37°C. One hundred L of duplicate recombinant human VEGF 165 or VEGF 165 b standards (R&D Systems) diluted in wash buffer (ranging from 15 pg/mL to 4 ng/mL) and blank (wash buffer) or sample were added to each well (Fig. 2B) . After incubation for 1 hour at 37°C and three washes as before, 100 L of biotinylated goat antihuman VEGF (0.025 g/mL in wash solution; R&D Systems), or 100 L of mouse anti-VEGF 165 b (0.025 g⅐mL -1 in wash solution, as described above) was then added to each well, and plates left for an additional hour at 37°C. After washing, 100 L of streptavidin-HRP (R&D Systems) 
Rabbit Corneal Angiogenesis Assay
MCF-7 cells were transfected with pcDNA 3 -VEGF 165 , pcDNA 3 -VEGF 165 b, or pcDNA 3 expression vector. Stable cell lines were selected in growth media containing 500 g/mL G418. VEGF 165 b lines expressed 17.8 fg/cell/hour, whereas VEGF 165 and pcDNA 3 lines expressed 4.9 and 0.08 fg/cell/hour, respectively. Corneal assays were done in female New Zealand albino rabbits (Charles River; Calco, Como, Italy). Cells were detached using trypsin and the reaction stopped by the addition of EMEM-10% FCS, followed by pelleting and suspension in EMEM-10% FCS. Cell suspensions containing 2.5 ϫ 10 5 cells per 5 L (n ϭ 4 eyes for each group) were implanted into a micropocket (1.5 ϫ 3 mm) incised into the cornea under local anesthesia (30 mg/kg sodium pentothal). Animals were observed every 2 days with a slit-lamp stereomicroscope, without anesthesia. Neovascular responses, presence of hyperemia and edema, and infiltration with inflammatory cells in the cornea were monitored. Positive angiogenic responses were scored according to the product of vessel density and distance from the limbus (in mm), as described previously (29) . Briefly, a density value of 1 corresponded to the presence of 0 to 25 vessels, a value of 2 to 25-50 vessels, a value of 3 to 50 -75 vessels, a value of 4 to 75-100 vessels, and a score of 5 to Ͼ100 vessels. The distance from the limbus was measured using an ocular grid.
Construction of Adenovirus
Adenovirus-expressing human VEGF 165 b was created with the AdEasy Vector system (Qbiogene, Inc., Nottingham, United Kingdom). Briefly, a reverse transcription-PCR fragment encoding a full-length coding region of VEGF 165 b was cloned into pShuttle-CMV and sequenced in both directions to confirm the correct sequence. pShuttle-CMV-VEGF 165 b was linearized with EcoRI and cotransformed with pAdEasy-1 into Escherichia coli (BJ5183). Recombinant clones were screened with kanamycin resistance and checked by restriction digest. Purified, correct pAd-VEGF 165 
Rat Mesenteric Angiogenesis Assay
Surgical Procedure. All surgical procedures were done under sterile conditions. Male Wistar rats (200 to 300 g) were anesthetized by inhalation of 5% halothane and maintained on 3% halothane. Body temperature was maintained at 37°C by a thermostatic heating pad and rectal temperature probe. After ventral laparotomy, part of the intestine was exteriorized and a mesenteric panel with few vessels was exposed under an intravital microscope (Leica DMIL). The panel was imaged with either a Nikon Coolpix 800 (Nikon Instruments) or a Leica DC350F (Leica, Bucks, United Kingdom) digital camera, and 25 L of virus (ϳ10 7 plaque forming units) were injected into the nearby fat pad with a Hamilton syringe fitted with a 30-gauge needle. Ad-VEGF 165 b, Ad-VEGF 165 (30) , or adenovirus-expressing enhanced GFP, (a kind gift of James Uney; University of Bristol) was used. In double infection experiments, 10 7 plaque forming units of each virus were injected into separate, nonoverlapping parts of the fat pad (to prevent co-infection and het- 
, the animal was re-anesthetized with halothane, and a laparotomy was done. The mesentery was exposed, and the virus injected panel located from Monastral blue injection sites and re-imaged.
Immunofluorescence on Whole Mount Mesentery. After imaging, the mesenteric panel was fixed in vivo with 4% paraformaldehyde for 5 minutes, and the rat killed by cervical dislocation. The same mesenteric panel was excised and additionally fixed for 30 minutes. Immediately after fixation, the mesentery was washed with 0.5% Triton X-100 in PBS (0. whole mount mesentery was imaged with a Leica Confocal Microscope (Leica confocal SP2 system; Leica), or Nikon E400 Eclipse epifluorescence microscope (Nikon). Proliferating endothelial cells, sprouts, and microvessels were imaged. VEGF 165 b secretion from the fat pad into the mesentery was checked by staining mesenteries with the anti-VEGF 165 b antibody (Fig. 3) .
Microvessel Analysis ؊ Percent Vessel Area Increase. The vessel area was measured using Openlab software (Improvision, Coventry, United Kingdom). The vessels were selected with the wand tool using a threshold of 32 pixels, and the area of these vessels was recorded. Fractional vessel area (FVA), used to measure the angiogenic effect of VEGF, was calculated from the vessel area as a percentage of the mesenteric area. Percent vessel area increase (%AI) was expressed as the difference between the FVA on day 7 and the FVA on day 1 as a percentage of the FVA on day 1.
%AI ϭ
FVA on day 7 Ϫ FVA on day 1
FVA on day 1 ϫ 100%
Microvessel Measurement. After immunofluorescence staining, the whole mount mesentery was used for microvessel measurement. For each mesentery, 8 to 12 views were selected randomly with a 40ϫ objective on a Nikon E400 Eclipse epifluorescence microscope and images were taken with the Nikon Coolpix 800 Digital Camera (Nikon, Surrey, United Kingdom). Openlab software (Improvision, Coventry, United Kingdom) was used to measure the area analyzed and vessel parameters between two adjacent branch points. The total vessels were counted and labeled, and the branch points, proliferating endothelial cells, and sprouts in each image were counted. The diameter and length of each vessel were measured. Branch point density, sprout density, and proliferating endothelial cell density were calculated as the number per unit area within five randomly selected fields of view (ϫ40 objective) containing vessels as described previously (31) .
Tumor Model
A total of 1 ϫ 10 6 A375 human melanoma cells stably transfected with 2.4 g of pcDNA3 (control) vector or pcDNA3-VEGF 165 or pcDNA3-VEGF 165 b (both expressing ϳ4 fg.cell -1 ⅐day -1 VEGF) was s.c. injected into each of six nude mice. To determine the effect of a mixture of populations, 5 ϫ 10 5 of VEGF 165 b and VEGF 165 -expressing cells were combined in PBS and injected as above. Tumor width and length was measured using Vernier's calipers, and tumor volume was calculated as the product of length width and the average of the two measurements. The mice were humanely killed once the tumors reached 16 mm in diameter or 28 days, whichever occurred soonest.
Statistical Analysis
One-way ANOVA was used to analyze the difference of parameters between the groups and Student Newmann Keuls post hoc test used to compare the individual groups. P Ͻ 0.05 was considered significant.
RESULTS

VEGF mRNA Distal Splice Site Selection Results in Endogenously Produced Proteins.
There have been many splice variants of VEGF described, four of which have been clearly demonstrated to be translated into protein-VEGF 189 , VEGF 165 , VEGF 121 , and large-VEGF (32, 33) . These are up-regulated in renal cancer (34) . We have shown that VEGF 165 b mRNA was down-regulated but not up-regulated in renal cancer (25) . To determine whether VEGF 165 b protein was expressed in normal and pathological tissues, we raised a mouse monoclonal antibody to the predicted nine COOH-terminal amino acids of human VEGF 165 b, the final six of which are specific to VEGF 165 b. This antibody was then used to probe a blot of an SDS-PAGE gel loaded with recombinant VEGF 165 b and VEGF 165 . Fig. 2A shows that this antibody specifically detects VEGF 165 b and does not detect VEGF 165 . This was true even in the presence of 50-fold greater amounts of VEGF 165 . To determine whether VEGF 165 b protein could be detected in normal human cells, this antibody was used on a Western blot analysis containing protein extracted from terminally differentiated conditionally immortalized human glomerular visceral epithelial cells (podocytes, a kind gift of Moin A. Saleem), which express VEGF 165 b mRNA (35) . The protein was then extracted from 10 6 cells and subjected to SDS-PAGE and Western blotting. The membrane was first probed with the VEGF 165 b antibody and then a commercial pan-VEGF antibody to ensure specificity. Fig. 4A shows that the antibody detected a number of different proteins, which appear to correlate with expected molecular masses for most isoforms of VEGF, including VEGF 121 b (monomer-band a, dimer-band b), VEGF 145 b (band c), VEGF 165 b (band d), VEGF 189 b (band e), and large VEGFbs (bands at f). The pan-VEGF antibody confirmed that these bands were VEGF isoforms (Fig. 4A) . These isoforms are consistent with VEGF 165 b, VEGF 189 b, VEGF 145 b, and VEGF 121 b. A larger molecular mass isoform, which corresponds to large-VEGF formed by alternate start codon usage (33) , was present in both blots. Interestingly, however, the relative intensities of the bands were different for the pan-VEGF antibody compared with the VEGF xxx b antibody. This suggests that the relative amount of the different splice forms is not the same for VEGF xxx b isoforms as for the conventional isoforms. Moreover, Western blotting of prostate tissue also demonstrated VEGF 165 b and other isoforms, showing that VEGF 165 b is expressed in human tissue (Fig. 4B) . We therefore speculate that podocytes and other human cells produce a sister family of inhibitory isoforms, including that to large-VEGF. We have described these as the VEGF xxx b family of isoforms. To determine whether the expression of VEGF xxx b also occurred in podocytes in human glomeruli, VEGF xxx b protein expression was detected in sections of nephrectomy specimens by immunohistochemistry. Fig. 4C shows clear expression of VEGF xxx b isoforms in the podocytes on the periphery of the glomerulus (arrows)-shown to be the location of VEGF expression by numerous studies (24) . (Fig. 4D) . To determine whether VEGF splicing was altered in prostate tissue, mRNA was extracted from transurethral resection of the prostate chips taken from 17 patients with benign prostatic hyperplasia and 9 with malignant prostate cancer. VEGF 165 b mRNA was found in 82% of the benign (14 of 17) but only 22% (2 of 9) of the malignant samples (P Ͻ 0.05, Fisher's exact test, three of each group shown in Fig. 4E ). VEGF 165 b is therefore an endogenously produced protein and is down-regulated at the mRNA level in prostate tumors. 165 (Fig. 5A) . To determine whether this was due to binding to the active signaling receptor VEGFR-2, we measured the ability of VEGF 165 both isoforms and subjected to immunoprecipitation with anti-phosphotyrosine antibodies and precipitate and supernatant probed for VEGFR-2 protein expression. Fig. 6A shows that VEGFR-2 was less phosphorylated by VEGF 165 b than VEGF 165 and was no more phosphorylated than untreated cells. Moreover, addition of both isoforms resulted in less phosphorylation than VEGF 165 alone or saline (P Ͻ 0.05, ANOVA, n ϭ 3). VEGF stimulates angiogenesis and vascular permeability by activating VEGFR-2. Human microvascular endothelial cells express both VEGFR-2 and VEGFR-1, which have been shown to interact. To determine whether VEGF 165 b inhibited VEGF 165 by inhibiting phosphorylation of VEGFR-2 directly, we measured the effect of VEGF 165 b on VEGFR-2 phosphorylation by incubating CHO cells transfected with VEGFR-2 with saline, VEGF 165 , VEGF 165 b, or both isoforms as above. Cells were then immunoprecipitated with anti-phosphotyrosine antibody and both supernatant and pellet subjected to Western blotting with an antibody to VEGFR-2. Fig. 6Bi shows that transfected cells have an endogenous level of phosphorylation of VEGFR-2 that is increased by VEGF 165 and decreased by VEGF 165 b. Moreover, VEGF 165 b incubation inhibited phosphorylation by VEGF 165 . VEGF 165 b Inhibits VEGF 165 -mediated VEGFR-2 Signaling. Phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK) by VEGFR-2 activation has been widely reported and appears to be necessary for alterations in cell behavior such as migration through extracellular matrix (36) , apoptosis (37) , and endothelial cell proliferation (38) , as well as in vivo properties of capillaries such as vascular compliance (39) VEGF 165 , or 40 ng⅐mL -1 of both isoforms or neither, the protein extracted, and subjected to SDS-PAGE and Western blotting, and immunoblotted with a phospho-p42/p44 MAPK antibody (Fig. 6Bii) . The blot was then stripped and reprobed with a p42/p44 MAPK antibody. Although treatment with VEGF 165 resulted in a significant increase in phospho-MAPK blot density, this was not the case for incubation with VEGF 165 b (Fig. 6Bii) . Moreover, treatment with both VEGF 165 and VEGF 165 b did not result in a significant increase in phosphorylation. Fig. 6Bii shows the mean density of the phosphop42/p44 MAPK band relative to total MAPK. Furthermore Fig. 6Biii shows that, unlike VEGF 165 , VEGF 165 b incubation did not result in phosphorylation of AKT, and incubation with both isoforms inhibited AKT phosphorylation compared with VEGF 165 treatment alone (P Ͻ 0.01, ANOVA; Fig. 6Biii ). This shows that VEGF 165 b can inhibit VEGF 165 -mediated signaling of at least two different pathways stimulated by activation of VEGFR-2. VEGF 165 has previously been shown to stimulate both Akt and p44/p42 MAPK phosphorylation in endothelial cells through VEGFR-2 activation (39 -41) . To determine whether VEGF 165 b could inhibit VEGF-mediated signaling in endothelial cells, human microvascular endothelial cells were treated with either saline, 1 nmol/L VEGF 165 , 1 nmol/L VEGF 165 b, or 1 nmol/L of each isoform for 20 minutes. Protein extracted from these cells was then subjected to SDS-PAGE and Western blotting and probed with antibodies to phospho-Akt and total Akt or phospho-MAPK and total MAPK (Fig. 7) . These studies showed that treatment with VEGF 165 resulted in greater phosphorylation than no treatment but treatment with VEGF 165 b did not. However, surprisingly VEGF 165 b did not appear to inhibit VEGF 165 -mediated phosphorylation of Akt (Fig. 7A) . Furthermore, VEGF 165 b treatment resulted in a significant increase in phosphorylation of p42/p44 MAPK, very similar to that elicited by VEGF 165 . Moreover, treatment with both isoforms also increased phosphorylation of MAPK to at least as great a level as treatment with either 1 nmol/L VEGF 165 or VEGF 165 b (Fig. 7B) .
VEGF 165 b Inhibits VEGF 165 -mediated Angiogenesis in the Eye. To determine the effect of VEGF 165 b on angiogenesis in vivo, we used two different assays. To determine whether cells transfected with VEGF 165 b could induce angiogenesis, MCF-7 breast cancer cells were transfected with an expression vector (pcDNA3) containing VEGF 165 b and implanted into the cornea of four New Zealand White rabbits (42) . Cells transfected with either pcDNA3 or pcDNA3-VEGF 165 were injected into the contralateral cornea. Fig. 8A shows examples of the vasculature of the cornea 10 days after implantation of the cells. pcDNA3-transfected cells showed no angiogenesis, whereas VEGF 165 -transfected cells expressing 2 fg⅐cell -1 ⅐day -1 VEGF 165 resulted in significant angiogenesis after 5 days that was marked by 10 days. VEGF 165 b-transfected cells expressing 12 fg⅐cell -1 ⅐day -1 on the other hand did not result in angiogenesis in the cornea (P Ͻ 0.001, two-way ANOVA; Fig. 8, A and C) . Moreover, when cells transfected with VEGF 165 b were mixed with cells transfected with VEGF 165 and implanted into the cornea, no angiogenesis was seen (Fig. 8B) , despite significant angiogenesis when VEGF 165 -transfected cells were mixed with pcDNA3-transfected cells and implanted (P Ͻ 0.0001, two-way ANOVA; Fig. 8, B and D) .
VEGF 165 b Inhibits VEGF 165 -mediated Angiogenesis in the Viscera. To determine whether VEGF 165 b could inhibit VEGF 165 -mediated angiogenesis in a separate assay in rats, we used a modification of a mesenteric angiogenesis assay (31) . Adenoviruses expressing EGFP, VEGF 165 b, or VEGF 165 were injected into the mesenteric fat pad of an anesthetized rat. In rats that received injections of adenovirus-expressing GFP, a small increase in visualized vascular area was seen (Fig. 9A, i to ii). When receiving injections of Ad-VEGF 165 , however, extensive and florid vasculature was induced in the adjacent mesenteric connective tissue panels (Fig. 9A , iii to iv) as shown previously (30) . In rats that received injections of Ad-VEGF 165 b, the increase in vasculature seen in the fat pad was no greater (Fig. 9A, v to vi) than that seen with control virus. Injection of both Ad-VEGF 165 b and Ad-VEGF 165 did not result in an increase in vascular area (Fig. 9A, vii to viii) . The perfused blood vessel area was significantly increased by Ad-VEGF 165 relative to adenovirus-expressing enhanced GFP but not by Ad-VEGF 165 b or both Ad-VEGF 165 b and Ad-VEGF 165 (P Ͻ 0.0001, ANOVA; Fig. 9B ). Quadruple fluorescent staining (e.g., Fig. 10A ) of the mesenteries with Griffonia simplicifolia isolectin B4 (stains endothelial cells), Ki-67 (proliferating cells), Hoescht (nuclei), and phalloidin (stains actin filaments in sprouts of endothelial cells undergoing migration) enabled quantification of parameters that require angiogenesis to occur. The density of branch points (Fig. 10B) , sprouts (Fig. 10C) , proliferating endothelial cells (Fig. 10D) , and blood vessels (Fig. 10E ) and the mean vessel length (Fig. 10F) were measured. VEGF 165 increased all of these measurements, except mean vessel length, which was decreased as expected if sprouting angiogenesis occurred. Injection of Ad-VEGF 165 b, however, did not result in an increase in perfused vessel area, vascular density, sprouting, branching, or proliferation and did not decrease mean vessel length. Moreover, when both viruses were injected, the effect of VEGF 165 on all these parameters was significantly inhibited (see Fig. 10B-F) .
Mimicking a Splicing Switch from VEGF 165 to VEGF 165 b Inhibits Tumor Growth In vivo. A375 melanoma cells, stably transfected with VEGF 165 b s.c. injected into each of six nude mice produced significantly smaller tumors (Fig. 11B ) than cells expressing VEGF 165 (Fig. 11A) . Moreover, injection of a mixture of the two isoform-expressing cells resulted in delayed tumor growth (Fig. 11C) , and at 20 days, the tumors were significantly smaller than in mice that received injections of VEGF 165 -expressing cells. (Fig. 11D) . Moreover, mixing the tumor cell populations resulted in growth at a slower rate, with an increased doubling time, suggesting that growth was inhibited by VEGF 165 b expression, not simply the number of cells developing into a tumor was different (Fig. 11E) .
DISCUSSION
Since its discovery in 1989 (43), VEGF has been regarded as the most potent and important angiogenic growth factor in both normal physiology and pathophysiological states (2, 3) . This has been due to the large numbers of studies investigating mRNA and protein expression in normal and pathological conditions and showing quite clearly that wherever angiogenesis occurs VEGF is expressed (8) . Moreover studies of the regulation of VEGF expression have clearly demonstrated that the driving force for expression of these growth factors is the physiologic requirement for increased vascularity-hypoxia (44) . Overexpression of VEGF results in increased angiogenesis and inhibition of VEGF results in inhibition of angiogenesis in normal and pathological states. Anti-VEGF agents have been demonstrated to be effective therapies in cancer (45) and other angiogenic conditions (46) . Despite this wealth of information, more than 11,000 scientific publications by the middle of 2004, there is still little known concerning the regulation of the different isoforms of VEGF. The evidence that an alternative splice site exists in the 3Ј-untranslated region of the VEGF mRNA that results in expression of isoforms with an alternate COOH terminus, which may be inhibitory and was down-regulated in renal carcinoma, suggested that regulation of splicing may be a regulatory mechanism of angiogenesis in cancer (25) . However, the presence of RNA sequence from a few individuals does not in itself show that a novel protein species is present nor the mechanisms underlying the inhibitory nature of VEGF 165 b. The results described here show that VEGF 165 b significantly inhibits VEGF 165 -mediated Fig. 9 . VEGF 165 b does not stimulate increased vascularity of mesenteric tissue and inhibits VEGF 165 -mediated increased vascularity. A, injection of adenovirus-expressing enhanced GFP (Ad-EGFP) resulted in a background level of angiogenesis on day 7 (ii) compared with day 1 (i). Ad-VEGF 165 injection resulted in florid angiogenesis 7 days (iv) after adenovirus injection (iii). Ad-VEGF 165 b injection did not result in any more angiogenesis on day 7 (vi) compared with day 1 (v) than EGFP (i to ii). Injection of both Ad-VEGF 165 b and Ad-VEGF 165 resulted in no greater angiogenesis on day 7 (viii) compared with day 1 (vii) than Ad-EGFP (i to ii). B, quantification of the increase in vessel area in six mesenteries showed that there was a significant increase in fractional vessel area in Ad-VEGF 165 compared with Ad-EGFP-injected mesenteries, which was not the case with either Ad-VEGF 165 b or combined Ad-VEGF 165 and Ad-VEGF 165 b injection (P Ͻ 0.01, ANOVA). activation of its major signaling receptor, VEGFR-2, and hence inhibits downstream signaling of VEGFR-2, such as MAPK activation, and physiological effects, such as angiogenesis. Surprisingly, VEGF 165 -mediated MAPK signaling in microvascular endothelial cells was the only pathway investigated that was not inhibited, suggesting that VEGF 165 b may be able to signal through VEGF-R1 or neuropilin to modulate VEGF 165 signaling, as has previously been described for placental growth factor (47) . The fact that only the six terminal amino acids are different suggests that it is these residues coded for by exon 8 proximal splicing sites that stimulate receptor signaling involved in these responses. Although one study showed that VEGF 121 (containing exon 8) was equally incapable as VEGF 110 in stimulating endothelial proliferation (26) , subsequent studies have shown that, in contrast, VEGF 121 is a highly potent angiogenic growth factor on endothelial cells in culture (48) and in vivo (42) . It is therefore quite possible that the six amino acids at the end of the VEGF sequence are required for full stimulation of the receptor, although not for binding to the receptor. It is still not clear whether the six amino acids coded for by exon 8 distal splicing are actively inhibitory or are simply not able to activate the receptor.
VEGF has been the most widely implicated protein in stimulating angiogenesis in cancer and other major health concerns of the developed world (3) . That VEGF can be differentially spliced to form an inhibitory isoform, which is endogenously expressed, and is antiangiogenic requires a major reevaluation of our current understanding of how angiogenesis is regulated. Because of the nature of this splice variant-distally splicing into the 3Ј-untranslated region of the VEGF mRNA, most previously investigated expression studies will not have distinguished VEGF xxx b from other isoforms. This may explain some of the data that does not show clear relationships between VEGF expression and angiogenesis, such as in melanoma and other angiogenic conditions (49) . Moreover, recent studies showing that VEGFneutralizing antibodies are an effective therapy for some types of cancer, retinopathy, and other angiogenic conditions (45, 46, 50, 51) could be made more effective by targeting the proangiogenic splice variants rather than a pan-VEGF strategy. There appears to be a splicing switch in at least two types of cancer-renal and prostatebut the mechanisms that regulate splicing of VEGF are almost completely unknown. Regulation of splicing from anti-to proangiogenic growth factor isoforms may be a component of the control of development of cancers, progression of heart disease, and other pathological states. It has not escaped our notice that other proteins involved in angiogenesis, such as VEGFR-1, fibroblast growth factor, fibronectin, and collagen (52) (53) (54) (55) (56) , also have differentially spliced inhibitory isoforms. A common mechanism may therefore exist for the regulation of these antiangiogenic splicing events. 
